Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines; D002469:Cell Separation; D004268:DNA-Binding Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D015789:HLA-A2 Antigen / Q000378:metabolism; D006433:Hemocyanins / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D008285:Major Histocompatibility Complex; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control*; D010455:Peptides / Q000737:chemistry; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000276:immunology; D019098:Telomerase / Q000235:genetics / Q000378:metabolism*; D014612:Vaccines
D019496:Cancer Vaccines; D004268:DNA-Binding Proteins; D015789:HLA-A2 Antigen; D010455:Peptides; D014612:Vaccines; D006433:Hemocyanins; D019098:Telomerase; C032808:keyhole-limpet hemocyanin